Fair-treatment and consumer-protection rules for patients and clinicians

Insys Therapeutics ran a speaker bureau for Subsys, a sublingual fentanyl spray approved for breakthrough cancer pain. Reps booked prescribers to speak; some of those events had no meaningful audience, and speaker selection tracked prescribing volume rather than teaching ability. In 2019 the company agreed to a $225 million resolution with the US Department of Justice and filed for bankruptcy days later. Its founder, John Kapoor, was convicted of racketeering conspiracy. Nothing in that case turned on a sentence sitting outside the approved label wording, which the claims lesson handles. The wrongdoing was the money.

Fairness duties run alongside the promotional rules and are enforced separately, under different statutes and different clauses. They ask two questions. Did you buy influence over a clinical decision? And did you lean on someone who could not push back?

Inducement: where the line actually falls

An inducement is anything of value given to a health professional, or to an organisation employing one, that could reasonably be expected to move a prescribing, purchasing or referral decision. Under the US Anti-Kickback Statute the test is unforgiving: if even one purpose of a payment is to induce referrals of a federally reimbursed product, the arrangement is criminal, however many legitimate purposes sit next to it. There is no comfort zone for mixed motives.

The ABPI Code has banned gifts and promotional aids to UK health professionals since the early 2010s. No pens, no mugs, no branded notepads. Hospitality must be secondary to the meeting itself, and the ABPI sets a UK subsistence ceiling in the region of £75 a head, which is a limit and not a budget to spend. Other national codes across Europe set their own figures; which code binds you in which market is mapped in the foundations lesson.

Payments to clinicians are not banned. Fees for advisory boards, market research, speaking, consultancy and trial work are all legitimate. What makes them defensible is paperwork created before the money moves: a written brief, a need identified by someone outside the sales line, selection criteria unrelated to prescribing volume, an hourly rate benchmarked to fair market value and applied consistently, and evidence the work was actually delivered. The substantiation file a sibling lesson describes proves a claim is true. Nothing in it proves a payment was fair.

Transparency of transfers of value

In the US, the Physician Payments Sunshine Act (2010) put manufacturer payments into Open Payments, published since 2014 and searchable by anyone. Since 2021 the reportable audience extends beyond physicians to physician assistants, nurse practitioners, nurse anaesthetists, nurse midwives and clinical nurse specialists. Reported industry spend runs into billions of dollars a year. In Europe, the EFPIA Disclosure Code drives national databases, including Disclosure UK, run by the ABPI since 2016.

The UK carries a failure mode worth planning for. Naming an individual requires their consent under data protection law, and roughly seven in ten give it, so a slice of payments surfaces only as an aggregate total. Two consequences follow. Your company's aggregate line can read worse than a competitor's purely because your consent rate is lower. And the adviser who refuses consent is often the one whose relationship would attract the most scrutiny. Have the consent conversation at contracting, not in the week reporting is due.

Publication also makes your engagement plan legible to outsiders. A journalist can run the same query you can: total fees by therapy area, concentration across the top ten recipients, repeat bookings. HHS OIG's Special Fraud Alert of November 2020 did exactly that, citing nearly $2 billion in speaker-related payments reported over a three-year period and warning that the speaker-programme format itself carries risk once food, travel and returning audiences are doing the work.

Vulnerable patients and undue influence

Purdue Pharma's 2020 federal resolution, around $8.3 billion in total, included a kickback conspiracy count. Payments went to prescribers through a speaker programme, and to an electronic health records vendor whose software prompted opioid prescribing at the point of care. Read the second part again: the inducement reached the patient through the clinician's screen, in a population already carrying dependence risk, and no patient in that room could have seen it. Undue influence does not need to touch the patient directly to harm them.

Where extra protection applies:

• Children and young people: address the parent and the clinician. Paediatric device messaging that appeals directly to the child is a straightforward breach in most codes.
• Newly diagnosed or terminally ill patients: messaging must not depend on fear or imply a survival benefit the data does not carry. Patient support programmes must stay clinical services, never enrolment funnels with per-patient economics.
• Cognitive impairment: in Alzheimer's and mental health, the decision often sits with an exhausted caregiver. Pressure tactics land harder there than anywhere else.
• Financial vulnerability: co-pay and access schemes are legitimate, but in the US, donations to nominally independent charity foundations have produced a long run of settlements where the charity's fund design tracked one manufacturer's product.

The FDA's Bad Ad program overview trains clinicians to report misleading promotion. Note what gets reported most often: things a rep said out loud, which no review workflow ever saw.

Medtech's own traps

Device selling puts the payment and the decision in the same room. Proctoring fees, consignment stock, evaluation units and royalty agreements with surgeon designers all have legitimate uses and all bend easily. The sharpest edge case is a surgeon who co-designed an implant, earns a royalty on it, and chooses it for their own operating list. Disclosure to the hospital and the patient is the minimum, and the royalty must not vary with that surgeon's own volume. OIG's 2013 alert on physician-owned distributorships called such arrangements inherently suspect, which is as close to a red light as US guidance gets.

When the funding becomes the message: Novo Nordisk and the PMCPA

In March 2023 the ABPI suspended Novo Nordisk's UK membership for two years. The PMCPA had found that a weight-management training course for health professionals in Wales, funded by the company, promoted Saxenda without making clear it was promotional, and the rulings included a breach of Clause 2, the finding that the industry has been brought into disrepute. That is the most serious outcome the UK code offers.

The cost was not a fine. Suspension removed the company from ABPI membership and its forums, brought an audit, and landed as a public censure at the moment obesity medicines were scaling commercially. Every subsequent conversation with an NHS partner started from that ruling.

The instructive part: educational funding is permitted, and the form of the arrangement was lawful. The fairness question is different. Could the clinician sitting in that course tell who had paid, and judge the content accordingly? A useful test before you sign a sponsorship: would an attendee know, before the first slide, who funded this and what they sell?

Failure modes a marketer owns

• Spend concentration. Nobody signs off a kickback. It emerges when the same twelve names collect fees quarter after quarter. Run that report yourself, monthly.
• Incentive design. Paying reps on the prescriptions of clinicians they also nominate as speakers creates the pattern regulators look for, whichever way the individual decisions went.
• Retrospective paperwork. A fair market value assessment written after the invoice reads as a cover story. Contracts belong in the dated sign-off sequence the pre-launch lesson sets out, before any work begins.
• Delegation. Agencies, contract sales teams and third-party distributors act for you. Insys was undone by field behaviour, not by a headquarters memo.
• Meeting drift. A satellite dinner that turns into a product pitch, or a patient-facing event where a prescription medicine gets named, breaks the rules regardless of the original agenda.

Putting it together

The compliant version of this work is dull on purpose. A named business need, a written brief, a rate you can defend to a stranger, a consent conversation held early, a disclosure line you would be content to see quoted. Insys and Purdue did not fail on wording. They failed on who was paid, how much, and why, and both ended in criminal exposure rather than a corrections letter.

Key takeaways

• One improper purpose is enough. Under the US Anti-Kickback Statute, a payment with legitimate elements is still criminal if inducement was any part of the intent.
• Gifts are gone in the UK, hospitality is capped in the region of £75 a head, and fees for service survive only with a pre-written brief and a benchmarked rate.
• Transparency is public and comparable: Open Payments since 2014, Disclosure UK since 2016, with UK naming dependent on consent that roughly seven in ten clinicians give.
• Vulnerability is a design constraint, not a tone. Purdue's 2020 resolution included inducements delivered through prescribing software to patients at risk of dependence.
• The severe penalty is exclusion, not a fine. Novo Nordisk's two-year ABPI suspension in 2023 followed a Clause 2 finding on a funded training course that read as promotion.